Barry D. Quart
Net Worth

Last updated:

What is Barry D. Quart net worth?

The estimated net worth of Dr. Barry D. Quart is at least $12,841,155 as of 13 Jan 2023. He owns shares worth $121,155 as insider and has received compensation worth at least $12,720,000 in Heron Therapeutics, Inc..

What is the salary of Barry D. Quart?

Dr. Barry D. Quart salary is $1,060,000 per year as Chairman & Chief Executive Officer in Heron Therapeutics, Inc..

How old is Barry D. Quart?

Dr. Barry D. Quart is 68 years old, born in 1957.

What stocks does Barry D. Quart currently own?

As insider, Dr. Barry D. Quart owns shares in one company:

Company Title Shares Price per share Total value
Heron Therapeutics, Inc. (HRTX) Chairman & Chief Executive Officer 94,652 $1.28 $121,155

What does Heron Therapeutics, Inc. do?

Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

HRTX logo
HRTX
Heron Therapeutics, Inc.
$1.28

Barry D. Quart insider trading

Heron Therapeutics, Inc.

Dr. Barry D. Quart has made 4 insider trades between 2013-2023, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 1,000,000 units of HRTX stock on 20 Nov 2013. As of 13 Jan 2023 he still owns at least 94,652 units of HRTX stock.

Transaction Date Security Shares Price per share Total value Source
Option
Common Stock 16,122 N/A N/A
Option
Common Stock 3,645 N/A N/A
Option
Restricted Stock Units 16,122 N/A N/A
Option
Restricted Stock Units 3,645 N/A N/A
Option
Restricted Stock Units 16,122 N/A N/A
Option
Restricted Stock Units 3,646 N/A N/A
Option
Common Stock 16,122 N/A N/A
Option
Common Stock 3,646 N/A N/A
Option
Common Stock 3,646 N/A N/A
Option
Restricted Stock Units 16,122 N/A N/A
Option
Restricted Stock Units 3,646 N/A N/A
Option
Common Stock 16,122 N/A N/A
Option
Restricted Stock Units 16,122 N/A N/A
Option
Common Stock 3,646 N/A N/A
Option
Restricted Stock Units 3,646 N/A N/A
Option
Common Stock 16,122 N/A N/A
Option
Common Stock 16,122 N/A N/A
Option
Restricted Stock Units 16,122 N/A N/A
Option
Common Stock 3,646 N/A N/A
Option
Restricted Stock Units 3,646 N/A N/A
Option
Restricted Stock Units 3,646 N/A N/A
Option
Common Stock 3,646 N/A N/A
Option
Restricted Stock Units 3,645 N/A N/A
Option
Common Stock 3,645 N/A N/A
Option
Common Stock 3,646 N/A N/A
Option
Restricted Stock Units 3,646 N/A N/A
Option
Common Stock 3,646 N/A N/A
Option
Restricted Stock Units 3,646 N/A N/A
Purchase
Common Stock 4,571 $17.5 $79,993
Option
Common Stock 19,675 N/A N/A
Option
Employee Stock Option (Right to Buy) 19,675 N/A N/A
Sale
Common Stock 50,000 N/A N/A
Option
Employee Stock Option (Right to Buy) 50,000 N/A N/A
Option
Common Stock 50,000 N/A N/A
Sale
Common Stock 100,000 N/A N/A
Option
Common Stock 100,000 N/A N/A
Option
Employee Stock Option (Right to Buy) 100,000 N/A N/A
Option
Common Stock 100,000 N/A N/A
Sale
Common Stock 100,000 N/A N/A
Option
Employee Stock Option(Right to Buy) 100,000 N/A N/A
Option
Common Stock 4,630 N/A N/A
Option
Employee Stock Option (Right to Buy) 4,630 N/A N/A
Option
Employee Stock Option (Right to Buy) 3,472 N/A N/A
Option
Common Stock 3,472 N/A N/A
Option
Stock Option (Right to Buy) 2,315 N/A N/A
Option
Common Stock 2,315 N/A N/A
Option
Common Stock 10,000 N/A N/A
Option
Stock Option (Right to Buy) 10,000 N/A N/A
Option
Stock Option (Right to Buy) 14,306 N/A N/A
Option
Common Stock 14,306 N/A N/A
Option
Stock Option (Right to Buy) 10,000 N/A N/A
Option
Common Stock 10,000 N/A N/A
Sale
Common Stock 10,000 N/A N/A
Purchase
Common Stock 10,000 N/A N/A
Purchase
Common Stock 1,000,000 N/A N/A

Heron Therapeutics key executives

Heron Therapeutics, Inc. executives and other stock owners filed with the SEC: